このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

血漿、末梢血単核細胞 (PBMC) および研究用のその他の標本を取得するためのアフェレーシスおよび標本収集手順

VRC 200: 研究用のヒト生体サンプルを取得するための多施設標本収集プロトコル

This study collects specimens from volunteers for use in studies by NIAID's Vaccine Research Center. A number of different types of specimens or samples can be collected, including blood, urine, body fluids or secretions, skin swabs, or skin biopsies. The samples are used for medical research, including the study of HIV, hepatitis, and other diseases; immune system responses, such as responses to vaccinations or infections; and for research on vaccine development.

Blood samples may be collected either by ordinary blood drawing (phlebotomy) or by apheresis, a procedure for collecting a larger quantity of blood cells or plasma than would be possible through simple blood drawing. For this procedure, the participant lies on a recliner or couch. Blood is removed through a needle in the vein of one arm and spun in a machine that separates out the desired component (plasma or white blood cells). The remainder of the blood is returned either through the same needle or through a needle in the other arm. The procedure takes about 1 to 3 hours.

Volunteers who are 18 years of age and older, including participants in other NIH research protocols, may be eligible. Individuals who have a condition that the research staff considers a reason not to make a sample donation will be excluded from the study.

Participants may have only one sample collected or may be asked to undergo repetitive sample collection procedures, depending upon the requirements of the particular research project for which the samples are being collected. Each individual's enrollment is for a 1-year period, which can be extended.

調査の概要

状態

募集

詳細な説明

Study Description:

This protocol is designed to collect human specimens, such as blood, mucosal secretions, skin swabs, skin biopsy, or body fluids to support medical research. These samples will be used by researchers, in their work on the development of vaccines and monoclonal antibodies, to study the correlates of immunity related to infectious diseases and allergies, and in laboratory work related to the development and/or validation of immunological and other relevant assays. Standard phlebotomy and apheresis procedures will be utilized to safely obtain necessary quantities of blood and cells.

Objectives:

To obtain human biological specimens such as blood (via phlebotomy), plasma or peripheral blood mononuclear cells (PBMC) samples (via apheresis), mucosal secretions, skin swabs, body fluids, and skin biopsy to support medical research.

Endpoints:

There are no specific endpoints in this study, as samples are collected for investigations conducted in research laboratories to address questions related to immunity and vaccine and monoclonal antibody development. Therefore, there is no analysis plan for this protocol. This protocol will be conducted in accordance with Good Clinical Practices for human research solely for the purpose of obtaining samples for research laboratories. Samples will be identified only by a participant identification number. Non-personally identifying information that will be linked to a participant ID only, such as demographic information, aspects of the medical history, laboratory parameters, recent immunizations or medications, genetic tests, and other medical information, may be provided to researchers if needed to support the objectives of the laboratory research.

研究の種類

観察的

入学 (推定)

3000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
    • Washington
      • Kirkland、Washington、アメリカ、98034
        • 完了
        • EvergreenHealth Medical Center
      • San Juan、プエルトリコ、00921
        • 積極的、募集していない
        • University of Puerto Rico Medical Sciences Campus

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Participants may be individuals participating solely in this protocol or may be individuals in other VRC studies from whom more cells are needed for research than can be collected by routine phlebotomy.At the VRC site, NIH employees and members of their immediate families may participate in this protocol. The UPR MSC site will only enroll participants from the community. Children are not eligible to participate in this clinical trial.

説明

  • INCLUSION CRITERIA FOR ADULT PARTICIPANTS:

A participant must meet all the inclusion criteria, as follows:

  1. Age 18 years or older
  2. Able and willing to complete the informed consent process
  3. Willing to provide blood or other samples that will be stored indefinitely and used for future research
  4. Able to provide proof of identity to the acceptance of the clinician completing the enrollment process; when informed consent is obtained by telephone or a telehealth visit, the investigator obtaining consent will also confirm proof of identity.

INCLUSION CRITERIA FOR CHILDREN:

  1. Children aged 3 to 17 years inclusive, and at least 12 kg in weight.
  2. Capability of the legal adult guardian of the child to understand and comply with the planned study procedures.
  3. Capability of the legal adult guardian of the child to provide written informed consent.
  4. Willing to have blood drawn or collection of urine, fecal samples, oral secretions, or swabs of mucosa that will be stored indefinitely and used for future research.
  5. The legal adult guardian of the children can provide proof of identity for the child and for themselves to the satisfaction of the clinician completing the enrollment process.

EXCLUSION CRITERIA FOR ALL PARTICIPANTS:

A participant will be excluded from protocol participation if there is presence of a condition that the attending physician considers to be a contraindication to the specimen collection procedures.

EXCLUSION CRITERIA FOR CHILDREN ONLY

  1. Acute or chronic illness that, in the opinion of the investigator or designee, precludes participation in the study.
  2. Factors related to the legal guardian that, in the judgment of the investigator or designee, may affect the objective decision-making of the legal guardian.

SKIN BIOPSY ELIGIBILITY CRITERIA FOR ADULTS ONLY:

The skin biopsy eligibility includes the following:

  1. Age 18 years or older
  2. No known allergies to the local anesthetic to be used
  3. No history of keloid formation
  4. No known coagulation disorders
  5. Not pregnant or breast feeding

APHERESIS ELIGIBILITY CRITERIA FOR ADULTS ONLY:

  • To undergo an apheresis procedure, a participant must have no medical contraindications. All apheresis procedures performed under this protocol are solely for research purposes.
  • Participants involved in an active clinical research protocol may participate in the apheresis protocol if the total amount of blood drawn does not exceed NIH guidelines or a site's institutional guidelines. A study clinician will complete a checklist for apheresis eligibility before referring a participant for apheresis.
  • At the NIH, prior to the scheduled procedure, the participant must have a venous assessment performed by apheresis staff to determine suitability for apheresis.

For Healthy Volunteers:

A healthy volunteer must meet all the following criteria prior to the procedure:

  1. Age 18 years or older
  2. Afebrile (temperature <= 37.5 degrees C)
  3. Weight >=110 pounds
  4. Adequate bilateral antecubital venous access
  5. Hemoglobin >= 12.5 g/dL for women; >= 13.0 g/dL for men within 56 days prior to apheresis procedure.
  6. Platelets > 150,000 K/uL within 56 days prior to apheresis procedure.
  7. No cardiovascular instability as indicated by a) history of medically significant cardiac arrhythmia within the last 12 months, or b) ischemic cardiovascular disease within the last 12 months, or c) heart rate outside of the 50-100 beats/minute interval (on 3 successive readings), or d) blood pressure greater than 180 mmHg (systolic) or 100 mmHg (diastolic) on 3 successive readings
  8. No current lung or kidney disease
  9. No known coagulation disorder
  10. No sickle cell disease
  11. No active or chronic hepatitis
  12. No intravenous injection drug use in the past 5 years
  13. Not breast feeding
  14. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) performed by a VRC study clinician within 72 hours prior to the apheresis procedure

Patients with an Infectious Disease:

A patient with an infectious disease must meet all the following criteria:

  1. Age 18 years or older
  2. Weight >= 110 pounds
  3. Afebrile (temperature <= 37.5 degrees C)
  4. Adequate bilateral antecubital venous access
  5. No cardiovascular instability as indicated by a) history of medically significant cardiac arrhythmia within the last 12 months, or b) ischemic cardiovascular disease within the last 12 months, or c) heart rate outside of the 50-100 beats/minute (on 3 successive readings), or d) blood pressure greater than 180/100 mmHg (on 3 successive readings)
  6. No current lung or kidney disease
  7. No known coagulation disorder
  8. No receipt of clotting factor concentrates in the past 5 years
  9. Hemoglobin >= 9.0 g/dL within 56 days prior to apheresis procedure
  10. Platelets >= 50,000 K/uL within 56 days prior to apheresis procedure
  11. White Blood Cell (WBC) >= 2.0 K/uL within 56 days prior to apheresis procedure
  12. Not breast feeding
  13. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) performed by a VRC study clinician within 72 hours prior to the apheresis procedure

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:OTHER
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
1

Sample collection only

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Sample collection only
時間枠:end of study

This protocol does not have an analysis primary outcome measure, but rather will be conducted in accordance with Good Clinical Practices for human research solely for the purpose of obtaining samples for research laboratories. Samples will be identified only by protocol identification number. Participant data, such as demographic information, aspects of medical history, laboratory parameters, recent immunizations or medications, HLA type, genetic tests and other medical information may be provided (identified by study number, but not subject name) to researchers if needed to support the objectives of the laboratory research.

end of study

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Lesia K Dropulic, M.D.、National Institute of Allergy and Infectious Diseases (NIAID)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2003年9月10日

試験登録日

最初に提出

2003年8月8日

QC基準を満たした最初の提出物

2003年8月8日

最初の投稿 (推定)

2003年8月11日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月24日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 030263
  • 03-I-0263

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する